TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26610844
Drug: Mefloquine 250‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 250‐mg weekly
Study: 26610844
Drug: Tafenoquine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine with a three‐day loading dose at 400‐mg
Study: 26610844
Drug: Tafenoquine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine with a three‐day loading dose at 400‐mg without follow-up weekly maintenance doses
Study: 24282608
Drug: Cochlear Implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear Implant (CI) before 5 years of age
Study: 24282608
Drug: Cochlear Implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear Implant (CI) after 5 years of age
Study: 24282608
Drug: Cochlear Implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear Implant (CI) with more than 5 years of implant use
Study: 24282608
Drug: Cochlear Implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear Implant (CI) regardless of age at implantation
Study: 18343056
Drug: Testosterone supplementation
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone supplementation in combination with hormone replacement therapy
Study: 18343056
Drug: Conventional postmenopausal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional postmenopausal hormone therapy
Study: 10971167
Drug: Cisplatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (20 mg/m(2)), Ifosfamide (1.5 g/m(2)), Irinotecan (60 mg/m(2)) with rhG-CSF support
Study: 10971167
Drug: Cisplatin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (15 mg/m(2)), Irinotecan (50 mg/m(2)) with rhG-CSF support (after dose adjustment)
Study: 8840939
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + bicarbonate
Study: 8840939
Drug: Insulin +
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin + saline
Study: 8840939
Drug: Albuterol +
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol + bicarbonate
Study: 8840939
Drug: Albuterol +
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol + saline
Study: 1473671
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no intravenous sedative)
Study: 25305728
Drug: MACS (magnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: MACS (magnetic activated cell sorting) with swim-up preparation
Study: 25305728
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (swim-up preparation)
Study: 19854483
Drug: 5% tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% tramadol (2 mg/kg) plus adrenaline (0.0125/mL)
Study: 19854483
Drug: 2% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% prilocaine plus adrenaline (0.0125/mL)
Study: 12359778
Drug: CAIV-T (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAIV-T (first dose)
Study: 12359778
Drug: CAIV-T (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAIV-T (second dose)
Study: 10426648
Drug: Indoramin 20
Normalized name: indoramin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoramin 20 mg orally twice a day
Study: 1969208
Drug: Ketoconazole shampoo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole shampoo, twice weekly for 4 weeks
Study: 7286046
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg) evening ingestion
Study: 7286046
Drug: Indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (100 mg) morning ingestion
Study: 27604762
Drug: Brilliant blue
Normalized name: Brilliant blue G
DrugBank: Brilliant blue G (DB15594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brilliant blue G (BBG)
Study: 21285719
Drug: Medical expulsive
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical expulsive therapy with alpha-blockers
Study: 18953506
Drug: Adjuvant sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant sodium selenite 0.2 mg kg(‐1) day(‐1) for 7 days in addition to chemotherapy
Study: 14982568
Drug: Intrathecal 10
Normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 10 mg of hyperbaric tetracaine with 0.2 mg of epinephrine (SE Group)
Study: 14982568
Drug: Intrathecal 10
Normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 10 mg of hyperbaric tetracaine (L Group)
Study: 14982568
Drug: Intrathecal 10
Normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 10 mg of hyperbaric tetracaine (S Group)
Study: 16758422
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of primary prophylaxis
Study: 16758422
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of secondary prophylaxis
Study: 9458381
Drug: 5-HT3-Receptor Antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5-HT3-Receptor Antagonist (5-HT3-RA)
Study: 9458381
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral metoclopramide (20 mg q.i.d.) + i.m. Dexamethasone (M + D)
Study: 2455099
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (CPA), 100 mg p.o./day plus tamoxifen (TAM), 100 mg p.o./day
Study: 2455099
Drug: Flutamide (FLU),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (FLU), 750 mg p.o./day
Study: 21275333
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (15-35 minute session with live patient-preferred music and therapeutic social interaction)
Study: 17560638
Drug: Conventional drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drugs (corticosteroids)
Study: 8478475
Drug: Argon laser
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon laser treatment for mature nodular port-wine stains, telangiectasia, small vascular lesions, and superficial pigmented lesions.
Study: 3928674
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E2) at 50 micrograms/24 h and higher
Study: 3928674
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E2) at 25, 50, 100, and 200 micrograms/24 h
Study: 29927201
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose proton pump inhibitor (PPI) - intravenous pantoprazole 80 mg bolus then continuously drip 8 mg per hour
Study: 29927201
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose proton pump inhibitor (PPI) - intravenous pantoprazole 40 mg twice daily
Study: 29927201
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose proton pump inhibitor (PPI)
Study: 29927201
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose proton pump inhibitor (PPI)
Study: 24118885
Drug: AZD7687 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7687 (1, 2.5, 5, 10 and 20 mg/day)
Study: 24118885
Drug: AZD7687 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7687 (doses >5 mg/day)
Study: 18331385
Drug: C-reactive protein
Normalized name: C-reactive protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-reactive protein thresholds (40, 60, 120 mg/l)
Study: 18331385
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of raised CRP concentration with clinical diagnosis of pneumonia
Study: 15944791
Drug: Platinum-based combination
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based combination chemotherapy (CTX)
Study: 15944791
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy (no-CTX)
Study: 15944791
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy (CTX)
Study: 15944791
Drug: Second-line chemotherapy
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-line chemotherapy (CTX)
Study: 12582393
Drug: Topical methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl aminolevulinate (MAL) 160 mg/g
Study: 30596964
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin suspension (50 mg/kg/day) for 3 days
Study: 30596964
Drug: Oral co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co-trimoxazole suspension (8 mg trimethoprim/kg and 40 mg sulfamethoxazole/kg/day) for 5 days
Study: 27813031
Drug: IV dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dexketoprofen trometamol (50 mg)
Study: 27813031
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen (1 gr)
Study: 27813031
Drug: No analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesic (Control Group K)
Study: 22617396
Drug: BOLUS (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOLUS (25 g of whey protein + 5 g of leucine dissolved in artificially sweetened water; 1 × 500 mL)
Study: 22617396
Drug: PULSE (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: PULSE (15 × 33‐mL aliquots of BOLUS drink every 15 min)
Study: 20033128
Drug: Transurethral microwave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral microwave therapy (TUMT)
Study: 15690909
Drug: Gepon 0.04%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepon 0.04% ointment
Study: 15690909
Drug: Immunomax 200
Normalized name: IMMUNOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomax 200 units intramuscularly, administered 3 times every 2nd day
Study: 15690909
Drug: Routine surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine surgical treatment and drug therapy (control group)
Study: 12577246
Drug: Intravenous amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amifostine (200 mg/m2/d in a short 3‐minute infusion 15 to 30 minutes before each fraction of radiotherapy)
Study: 12577246
Drug: Subcutaneous amifostine
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous amifostine (500 mg/d in two, slow 1.25‐mL injections at two different sites 20 to 60 minutes before each radiotherapy fraction)
Study: 27094489
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment specified)
Study: 23505124
Drug: Aripiprazole 9.75
Normalized name: ARIPIPRAZOLE 9.75MG/1.3ML (7.5MG/ML) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 9.75 mg IM injection
Study: 21682350
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (two NRTIs + DRV/r)
Study: 15900378
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 40 mg/kg/day in 5% dextrose
Study: 8688215
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with cisplatin (100 mg/m2, D1) and fluorouracil (1 g/m2, D2‐4) followed by regional treatment
Study: 8688215
Drug: Regional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regional treatment alone
Study: 22115397
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral therapy initiation
Study: 29076171
Drug: Yoga intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yoga intervention (2 sessions weekly for 12 weeks)
Study: 25017530
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS) 110 mcg once daily
Study: 17400672
Drug: Supplemental O2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental O2 therapy
Study: 15724143
Drug: High-dose levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose levothyroxine (L-T(4)), mean dose 320 microg/day, adjunctive treatment for 7 weeks
Study: 15724143
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (age-matched healthy women without L-T(4) treatment)
Study: 9471040
Drug: Casodex 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex 100 mg daily
Study: 9471040
Drug: Casodex 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex 200 mg daily
Study: 9471040
Drug: Casodex (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex (all doses)
Study: 7613148
Drug: Oral provocation
Normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral provocation tests (OPTs) with the suspected drug
Study: 7613148
Drug: Concomitant ARs
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant ARs to other mild analgesics during OPTs
Study: 7613148
Drug: Oral provocation
Normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral provocation tests (OPTs)
Study: 7613148
Drug: Standard battery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard battery of different analgesics in OPTs
Study: 7613148
Drug: Single preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preparation recommendation (e.g., acetaminophen) without OPT
Study: 31298405
Drug: 40:1 MI/DCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40:1 MI/DCI ratio, 2 g of inositols twice a day for 3 months
Study: 28091438
Drug: 0.75 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 ml/kg of 0.25% bupivacaine
Study: 28091438
Drug: 0.5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml/kg of 0.25% bupivacaine
Study: 27443567
Drug: Cinacalcet (CC)
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet (CC) with Sevelamer (SV)
Study: 27443567
Drug: Cinacalcet (CC)
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cinacalcet (CC) with Calcium Salts (CS)
Study: 17624996
Drug: Single-blind placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-blind placebo administration
Study: 10624256
Drug: Risk assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk assessment and classification of pressure ulcers performed daily by nurses using the Modified Norton Scale (MNS) and a 'Pressure Ulcer Card'.
Study: 7611822
Drug: Topical IFN
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical IFN gamma-1 beta gel
Study: 31441893
Drug: BoNTA injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BoNTA injection (5 IU/cm)
Study: 27683185
Drug: Calcium (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (2000 mg) and Vitamin D (1000 IU) supplementation
Study: 26123629
Drug: Gabapentin (100-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (100-600 mg/day)
Study: 26123629
Drug: Clonazepam (0.5-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.5-2 mg/day)
Study: 23175556
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate 6 mg/kg/d (once-daily or twice-daily) for 7 days
Study: 23175556
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate 8 mg/kg/d (once-daily or twice-daily) for 3 days, followed by mefloquine
Study: 23175556
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms (including both doses and schedules)
Study: 15532847
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus preoperative treatment with recombinant human IL‐2 (9,000,000 IU for three consecutive days)
Study: 15532847
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus preoperative treatment with recombinant human IL‐2
Study: 11804379
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for small-cell lung cancer (SCLC)
Study: 11804379
Drug: Surgery or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery or palliative chemotherapy for non-small-cell lung cancer (NSCLC)
Study: 11804379
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of life measurement tools (EORTC LC-13, FACT-L, LCSS)
Study: 7894627
Drug: 0.05% levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% levocabastine eye drops and nasal spray plus topical placebos (twice daily)
Study: 7894627
Drug: 2% sodium
Normalized name: Dextrose 5% and 0.2% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% sodium cromoglycate eye drops and nasal spray (four times daily)
Study: 3499074
Drug: Sucralfate suspension
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate suspension (1 g/10 ml every four hours)
Study: 3499074
Drug: Antacid titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid titration (to maintain a gastric pH of more than 4)
Study: 21076278
Drug: Etravirine (ETR)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine (ETR) 400 mg daily
Study: 9262126
Drug: Dextromethorphan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (150 mg daily)
Study: 30938645
Drug: SDF solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDF solution
Study: 30938645
Drug: SDF solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDF solution followed by potassium iodide (KI) solution
Study: 15741544
Drug: Mirazid (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirazid (300 mg/day for three consecutive days)
Study: 15741544
Drug: Praziquantel (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (single dose of 40 mg/kg)
Study: 12875093
Drug: Home enteral
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home enteral nutrition (HEN) with a mean of 1650 Kcal of enteral solution
Study: 7762065
Drug: Enisoprost (EP)
Normalized name: acetaminophen
DrugBank: Enisoprost (DB19319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enisoprost (EP) 100 mg p.o. t.i.d. for 12 weeks
Study: 28110408
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment with distraction osteogenesis (DO)
Study: 17596694
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Iscador therapy)
Study: 10093796
Drug: Intraarticular injections
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injections of sodium hyaluronate (20 mg) plus steroid (20 mg triamcinolone acetonide) and physiotherapy
Study: 10093796
Drug: Intraarticular injections
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injections of steroid (20 mg triamcinolone acetonide) alone and physiotherapy
Study: 2945705
Drug: 1% metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% metronidazole in an emollient cream base
Study: 2945705
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg oral tetracycline taken twice daily
Study: 27016729
Drug: First-generation antipsychotics
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotics (haloperidol and flupentixol)
Study: 27016729
Drug: Second-generation antipsychotics
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotics (olanzapine, aripiprazole and quetiapine)
Study: 20473735
Drug: Xuezhikang Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang Capsule (600 mg, twice a day) and Valsartan (80 mg once a day)
Study: 20473735
Drug: Xuezhikang Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang Capsule and Valsartan vs Control group
Study: 20473735
Drug: Xuezhikang Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang Capsule and Valsartan vs Valsartan group
Study: 15470940
Drug: School-based drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based drug abuse prevention program
Study: 15470940
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no drug prevention program)
Study: 30159739
Drug: Knee brace
Normalized name: Knee Brace Large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee brace (12 weeks postoperative therapy)
Study: 30159739
Drug: Wedge insoles
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wedge insoles (12 weeks postoperative therapy)
Study: 30159739
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific postoperative therapy (control group)